Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Pulmonx, Inc.
Information provided by (Responsible Party):
Pulmonx, Inc. Identifier:
First received: February 20, 2013
Last updated: July 31, 2014
Last verified: July 2014

The purpose of this research is to study a medical device that is designed to produce lung volume reduction. This device is called the PulmonX Endobronchial Valve (EBV). It has not been approved by the Food and Drug Administration (FDA) and is considered investigational. The EBV is a one-way valve that blocks off the diseased lung section to inhaled air but lets the trapped air already inside the area escape. With placement of the EBV, the diseased part of the lung collapses which allows the healthier parts of the lung to expand.

The EBV can be placed by a doctor in a diseased section of the lungs using bronchoscopy. Bronchoscopy is a way to access the lungs using a small tube with a camera on the end. With bronchoscopy, a physician can reach the airways in the lung by passing the tube through either the mouth or nose. Use of bronchoscopy for performing lung volume reduction may have fewer risks than surgery and have reduced recovery time.

This study is designed to investigate the safety and effectiveness of the Pulmonx EBV for treating emphysema symptoms as compared to a standard medical therapy program alone. It is hypothesized that after placement of the EBV, lung function will be improved as compared to standard medical therapy alone.

Condition Intervention
Device: EBV
Other: Optimal Medical Management

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Lung Function Improvement After Bronchoscopic Lung Volume Reduction With Pulmonx Endobronchial Valves Used in Treatment of Emphysema

Resource links provided by NLM:

Further study details as provided by Pulmonx, Inc.:

Primary Outcome Measures:
  • Forced expiratory volume in 1-second (FEV1) [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Volumetric reduction of the treated area of the lung [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • St. George's Respiratory Questionnaire (SGRQ) [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • 6-minute walk distance [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • Adverse Events [ Time Frame: 1 Year ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 183
Study Start Date: July 2013
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: EBV and Optimal Medical Management
This study arm will undergo EBV treatment along with optimal medical management, including smoking cessation program, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
Device: EBV
This study arm will undergo EBV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
Optimal Medical Management
This study arm will receive maximal medical management, including smoking cessation program support if necessary, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
Other: Optimal Medical Management
This study arm will receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.


Ages Eligible for Study:   40 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical and radiological evidence of emphysema
  • Currently non-smoking
  • Stable on current medication regimen
  • Forced expiratory volume in one second (FEV1) between 15% and 45% of predicted value

Exclusion Criteria:

  • Had two or more hospitalizations over the last year for a COPD exacerbation
  • Had two or more hospitalizations over the last year for pneumonia
  • Had a prior lung transplant, lung volume reduction surgery, bullectomy or lobectomy
  • Had a heart attack or congestive heart failure within the last 6 months
  • Have heart arrhythmia
  • Is alpha-1 antitrypsin deficient
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01796392

United States, Alabama
The University of Alabama at Birmingham Recruiting
Birmingham, Alabama, United States, 35249
Contact: Patti Smith, RN, BSN    205-996-5392   
Contact: Necole Harris    205-934-9240   
Principal Investigator: Mark Dransfield, MD         
United States, Arizona
Arizona Pulmonary Specialists Recruiting
Phoenix, Arizona, United States, 85012
Contact: Terry Thomas    602-240-3383   
Principal Investigator: Richard Sue, MD         
United States, California
University of Southern California Recruiting
Los Angeles, California, United States, 90033
Contact: Michelle Hernandez, BA, CCRP    323-442-6252   
Principal Investigator: M. Paul McFadden, MD         
University of California at Davis Medical Center Recruiting
Sacramento, California, United States, 95817
Contact: Tina Tham    916-734-3351   
Principal Investigator: Brian Morrissey, MD         
University of California, San Diego Recruiting
San Diego, California, United States, 92103
Contact: Anne Powers, RN    619-543-2291   
Principal Investigator: Samir Makani, MD         
University of California, San Francisco Recruiting
San Francisco, California, United States, 94143
Contact: Gabriela Dincheva    415-353-7995   
Contact: Archer Eller, MS    415-502-2025   
Principal Investigator: Steven Hays, MD         
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Recruiting
Torrance, California, United States, 90502
Contact: Rafi Kiledjian, MD    310-222-8200   
Principal Investigator: David Hsia, MD         
United States, Illinois
Southern Illinois University School of Medicine Recruiting
Springfield, Illinois, United States, 62781
Contact: Cathy Leslie    217-545-5000   
Principal Investigator: Stephen Hazelrigg, MD         
United States, Kentucky
University of Louisville Research Foundation Recruiting
Louisville, Kentucky, United States, 40202
Contact: Crissie Despirito, RN    502-852-0026   
Principal Investigator: Tanya Wiese, DO         
United States, Massachusetts
St. Elizabeth's Medical Center of Boston Recruiting
Boston, Massachusetts, United States, 02135
Contact: Arthur Dea    617-789-2078   
Principal Investigator: Samaan Rafeq, MD         
United States, Michigan
Henry Ford Hospital Recruiting
Detroit, Michigan, United States, 48202
Contact: Roel-Rolando Almario, RN, BSN    313-916-2433   
Contact: Lana Saugrich, RN    313-916-2433   
Principal Investigator: Michael Simoff, MD         
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Emily Smathers    919-668-3812   
Principal Investigator: Momen Wahidi, MD         
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
Contact: Yvonne Meli, RN    216-445-4215   
Principal Investigator: Michael Machuzak, MD         
United States, Pennsylvania
Temple University Hospital Recruiting
Philadelphia, Pennsylvania, United States, 19140
Contact: Helga Criner, RN, BSN    610-630-2222   
Principal Investigator: Gerard Criner, MD         
United States, Washington
Swedish Thoracic Surgery Recruiting
Seattle, Washington, United States, 98104
Contact: Tina Brennan    206-386-2450   
Principal Investigator: Jed Gorden, MD         
Sponsors and Collaborators
Pulmonx, Inc.
Principal Investigator: Gerard Criner, MD Temple University Hospital, Philadelphia, PA
Principal Investigator: Armin Ernst, MD Reliant Medical Group, Worcester, MA
  More Information

No publications provided

Responsible Party: Pulmonx, Inc. Identifier: NCT01796392     History of Changes
Other Study ID Numbers: 600-0012
Study First Received: February 20, 2013
Last Updated: July 31, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Pulmonx, Inc.:
endobronchial valve
pulmonary rehabilitation

Additional relevant MeSH terms:
Pulmonary Emphysema
Lung Diseases
Lung Diseases, Obstructive
Pathologic Processes
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases processed this record on November 27, 2014